Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...

From monoclonal antibodies (mAb) to recombinant proteins ... biologics offers a cost-effective solution. The market for ‘biosimilars’ is booming in China and across the world.

Antidrug antibodies may interfere with the efficacy of these agents. Future therapies will hopefully include cheaper biosimilars, which have only been recently become available in some countries.

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

positioning Amneal to have a portfolio of six biosimilars across eight product presentations by 2027. Denosumab is a monoclonal antibody drug that inhibits bone reabsorption. It is indicated for ...

CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian ...